One of the US Food and Drug Administration’s latest warning letters revisits a topic commonly noted in dietary supplement facility inspections but absent from warnings posted during the COVID-19 pandemic: contract manufacturers don’t ensure own labelers’ regulatory compliance.
The Office of Regulatory Affairs East Division 3 district office in Atlanta found good manufacturing practice and labeling problems during...





